ArdelyxARDX +1.93%75 FCF Margin % is -34.20% as of Mar. 2026. GuruFocus rates ARDX with a GF Score™ of 75/100 and a GF Value™ of $10.20 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 955 Biotechnology companies, Ardelyx ranks better than 68.8% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Ardelyx's Free Cash Flow for the
three
months ended in Mar. 2026 was $-32.3 Mil. Ardelyx's Revenue for the
three
months ended in Mar. 2026 was $94.5 Mil. Therefore, Ardelyx's FCF Margin % for the quarter that ended in Mar. 2026 was -34.20%.
The historical rank and industry rank for Ardelyx's FCF Margin % or its related term are showing as below:
ARDX'
s FCF Margin % Range Over the Past 10 Years
Min: -2707.52 Med: -160.82 Max: -8.77
Current: -8.77
During the past 13 years, the highest FCF Margin % of Ardelyx was -8.77%. The lowest was -2707.52%. And the median was -160.82%.
ARDX's FCF Margin % is ranked better than 68.8% of 955
companies
in the Biotechnology industry
Industry Median: -84.65
vs ARDX: -8.77
Ardelyx FCF Margin % Related Terms
Ardelyx FCF Margin % Historical Data
* Premium members only.
The historical data trend for Ardelyx's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Ardelyx's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ardelyx FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ardelyx's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Ardelyx's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ardelyx (ARDX) has a FCF Margin % of -34.20% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #298 out of 955 companies in the Biotechnology industry, placing it in the top 31.2%.
Is Ardelyx's FCF Margin % too high?
Ardelyx's current FCF Margin % is -34.20%. Based on the distribution chart, Ardelyx ranks #298 out of 955 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ardelyx has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's FCF Margin % compare to AVLN and INBX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #298 out of 955 companies for FCF Margin %. This puts Ardelyx in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Ardelyx and its competitors. Ardelyx's current FCF Margin % is -34.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is $10.20, compared to a current price of $5.27 — trading 48.3% below its estimated fair value. The current FCF Margin % is -34.20%. Ardelyx's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Ardelyx (ARDX), the current FCF Margin % is -34.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ardelyx (ARDX) Overvalued in 2026?
Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued.
The current stock price of $5.27 is trading 48.3% below its estimated GF Value™ of $10.20.
GuruFocus considers Ardelyx to be Possible Value Trap.
Key valuation signals for ARDX:
FCF Margin %: -34.20%
GF Value™: $10.20 vs. price of $5.27 (48.3% below fair value)
No single metric tells the full story. See the ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
75GF Score
Get the complete analysis for ARDX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ARDX has been successfully added to your 
